Lipocine Inc
$ 2.31
-2.53%
28 Apr - close price
- Market Cap 19,019,500 USD
- Current Price $ 2.31
- High / Low $ 2.35 / 2.24
- Stock P/E N/A
- Book Value 2.35
- EPS -1.77
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.54 %
- 52 Week High 12.37
- 52 Week Low 1.81
About
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceuticals for the treatment of metabolic and endocrine disorders. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$6.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-11-06 | 2025-08-05 | 2025-05-07 | 2025-03-05 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-08 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.42 | -0.59 | -0.41 | -0.35 | 0.33 | -0.41 | -0.57 | 0.66 | -0.42 | -1.27 | -0.68 | -0.68 |
| Estimated EPS | -0.61 | -0.54 | -0.4 | -0.35 | -0.4 | -0.48 | -0.78 | -0.68 | -0.47 | -0.6 | -0.64 | -0.42 |
| Surprise | 0.19 | -0.05 | -0.01 | 0 | 0.73 | 0.07 | 0.21 | 1.34 | 0.05 | -0.67 | -0.04 | -0.26 |
| Surprise Percentage | 31.1475% | -9.2593% | -2.5% | 0% | 182.5% | 14.5833% | 26.9231% | 197.0588% | 10.6383% | -111.6667% | -6.25% | -61.9048% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LPCN
2026-04-28 10:38:55
Lipocine Inc. (LPCN) announced the publication and discussion of its LPCN 1148 manuscript at The Liver Meeting 2024 Editor's Cut Session. This news was delivered via Quantisnow, a real-time market data platform for retail investors. The article also provides recent analyst ratings and SEC filing updates for Lipocine.
2026-04-26 20:39:39
Lipocine's stock plummeted after its drug LPCN 1154 failed to meet the primary endpoint in a Phase 3 study aimed at managing preterm labor. This clinical setback significantly impacted the company's market valuation.
2026-04-21 20:40:25
Lipocine Inc. has announced its 2026 Annual Meeting of Stockholders on June 3, 2026, where it will seek votes on the election of four directors, the ratification of Tanner LLC as its 2026 auditor, and an advisory "say-on-pay" vote for executive compensation. A key proposal includes amending its 2014 Stock and Incentive Plan to increase the total shares authorized for issuance from 600,000 to 1,000,000 and raising the annual individual award limit from 25,000 to 100,000 shares. The Board unanimously recommends voting in favor of all proposals, emphasizing the importance of equity compensation for attracting and retaining talent.
2026-04-21 20:05:13
Lipocine Inc. announced that Dr. Spyros Papapetropoulos resigned from its Board of Directors on April 16, 2026, due to competing professional commitments and differing views on the company’s strategic direction. Dr. Papapetropoulos had served as Chairman, Lead Independent Director, and a member of the compensation committee since 2022. The Board subsequently appointed R. Dana Ono as the new Chairman and Lead Independent Director on April 20, 2026, ensuring continuity in independent leadership.
2026-04-08 16:09:37
John W. Higuchi, Director of Lipocine Inc. (LPCN), purchased 40,000 shares worth $81,199 on April 7, 2026, as the stock trades near its 52-week low and is considered undervalued according to InvestingPro. This comes after the company's postpartum depression drug candidate, LPCN 1154, failed to meet its primary endpoint in a Phase 3 trial, despite showing a positive safety profile. H.C. Wainwright, however, raised its price target for Lipocine to $15 from $7, maintaining a Buy rating.
2026-04-07 05:09:30
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN) following a significant stock price decline. The investigation focuses on whether Lipocine's executive officers complied with federal securities laws after the company announced its Phase 3 trial for LPCN 1154 failed to meet its primary endpoint, resulting in investor losses. Shareholders who purchased Lipocine securities and suffered losses are encouraged to contact the firm for more information.
